Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals completed patient enrollment in its Phase 3 C-FORWARD trial evaluating the BEM/RZR regimen for hepatitis C, enrolling more than 880 patients across 17 countries. Topline results from C-FORWARD are expected around year-end 2026, while data from the North American C-BEYOND trial remains on track for mid-year 2026.
Key figures
- Drug Name
- Bemnifosbuvir and Ruzasvir (BEM/RZR)
- Phase Of Trial
- Phase 3
- Countries
- 17
- Clinical sites
- approximately 120
- Patients enrolled
- More than 880
- Topline results c beyond
- mid-year 2026
- Topline results c forward
- year-end 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.